---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Co-prescribed/Concomitant therapies. Topics: Prohibited treatments and washout periods in the STRIDE protocol, Duration of the medication restrictions and recording of concomitant medications in the STRIDE protocol, Acid-reducing agents and antiviral medications in the STRIDE protocol, Permitted vaccinations and dietary restrictions in the STRIDE protocol, and 1 further topic. 5 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Prohibited treatments and washout periods in the STRIDE protocol

| Treatment category | Examples | Washout period before randomization |
| --- | --- | --- |
| “Topical medications or treatments that could affect psoriasis evaluation” | “corticosteroids, anthralin, calcipotriene, vitamin D derivatives, retinoids” | “2 weeks” |
| “Phototherapy or systemic medications or treatments that could affect psoriasis evaluation” | “oral or injectable corticosteroids, retinoids, 1,25-dihydroxy vitamin D3” | “4 weeks” |
| “Therapeutic agents targeted to IL-12 or IL-23” | “ustekinumab, guselkumab, tildrakizumab, risankizumab” | “6 months” |
| “Therapeutic agents targeted to IL-17” | “secukinumab, ixekizumab, brodalumab” | “4 months” |
| “TNFα inhibitors” | “etanercept, infliximab, adalimumab” | “2 months” |
| “Systemic immunosuppressants or immunomodulatory drugs” | “corticosteroids (oral/IV/IM/SC), methotrexate, azathioprine, cyclosporine, mycophenolate mofetil” | “4 weeks or 5 half-lives” |
| “Agents that modulate B cells” | “rituximab, ocrelizumab” | “6 months” |
| “Agents that modulate T cells” | “abatacept, alemtuzumab” | “3 months” |
| “JAK inhibitors or TYK2 inhibitors” | “baricitinib, tofacitinib, upadacitinib, ruxolitinib, fedratinib, deucravacitinib” | “4 weeks” |
| “Investigational agents” |  | “30 days or 5 half-lives” |
| “Proton pump inhibitors” | “omeperazole, esomeprazole, pantoprazole” | “Prior to Study Day 1” |

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-2"></a>

### Duration of the medication restrictions and recording of concomitant medications in the STRIDE protocol

> “Medication and treatment restrictions applicable before the dosing period are listed as exclusion criteria in Section 5.3. These restrictions are applicable for the duration of the study and are summarized in Table 2.”
> “Prior and concomitant medication as well as vaccination use after screening will be recorded on the prior and concomitant eCRF.”
> “Prior medications should be collected from the past 10 years.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-3"></a>

### Acid-reducing agents and antiviral medications in the STRIDE protocol

> “The use of Proton Pump Inhibitors (PPIs) are not permitted on study due to the potential to decrease ESK-001 exposure.”
> “However, the use of H2 blockers (e.g., famotidine or ranitidine) and calcium carbonate-containing antacids (eg, Tums”
> “are allowed during the study but should be taken at least 2 hours after a dose of study drug.”
> “Based on in vitro assessments, ESK-001 has the potential for drug-drug interaction with antiviral medications metabolized through CYP3A4, CYP2D6 and P-gp pathways (eg, Paxlovid [nirmatrelvir + ritonavir]).”
> “The benefit:risk assessment for administration of anti-viral medications with a narrow therapeutic index should be discussed with the medical monitor whenever possible.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-4"></a>

### Permitted vaccinations and dietary restrictions in the STRIDE protocol

> “Inactivated vaccines (including but not limited to COVID-19 vaccines and boosters) will be allowed while on study.”
> “Foods such as star fruit juice, Seville orange juice, and grapefruit juice that are strong to moderate inhibitors of P450 (CYP) 3A4 should be avoided.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-5"></a>

### Discontinuation of study drug for new chronic psoriasis medication in the STRIDE protocol

> “Patients should discontinue study drug for any of the following reasons:”
> “Use of any medication, intended to chronically treat psoriasis (refer to Section 6.12.2), other than those documented at screening”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
